Stock Ratings / Industrials / DBD / options

PBI (64) NATL (55) VYX (31) PAR (31) ⌘ Pro Terminal →

Diebold Nixdorf Incorporated (DBD) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is DBD trading relative to its 50-day, 200-day, and 52-week technical levels?

DBD last traded at $59.14 (+1.84% on volume of 685,821 shares), positioning the stock -8.93% below its 50-day simple moving average ($64.94) and -21.05% below its 200-day simple moving average ($74.91). Across its 52-week range of $52.87 to $92.08, DBD sits at the 16.0% percentile with a 14-day RSI of 39.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($54.35 to $63.93).

Q: What is DBD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for DBD.

$59.14 +1.84% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $59.22

Diebold Nixdorf Incorporated (DBD) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.99B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DBD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Diebold Nixdorf Incorporated (NYSE: DBD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $59.14 (+1.84% 1D, market cap $1.99B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, DBD ranks #226 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DBD compare to PBI and NATL in the Industrials sector?

▼

Within the Industrials sector (Office Equipment/Supplies/Services), DBD carries a Roarable D+ (52/100 RQD), trailing P/E of 21.0x, gross margin of 25.3%, and ROIC of 11.5%. By comparison, PBI (Pitney Bowes Inc.) holds a C grade (64/100 RQD, P/E 15.6x, ROIC —, cap $2.26B) and NATL (NCR Atleos Corporation) posts a D+ grade (55/100 RQD, P/E 20.9x, ROIC 14.4%, cap $3.38B). Among the 5-stock peer group, PBI leads on earnings multiple (15.6x) while NATL leads on capital efficiency (14.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DBD?

▼

Per DBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000028823), Diebold Nixdorf Incorporated generated $3.81B in revenue (+1.5% YoY), $94.6M in net income, and $300.7M in free cash flow against $3.85B in total assets and $938.5M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $59.22 (+0.14%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 7.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DBD)Realized 20D OHLCV Swing Band: ±8.1%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY DBD SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (31% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (23% of score)

Altman Z-Score 1.79 (DISTRESS RISK (<1.8)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$63.26+6.8% Next Q

Q2 (-2Q)

Grade C$67.57+1.8% Next Q

Q3 (-1Q)

Grade C$68.82-14.1% Next Q

Current

Grade D+$59.14-1.1% Hist 90D α

Trajectory: C (60) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DBD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DBD currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Company leadership has skin in the game with net positive insider conviction.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($64.94) and Max Pain ($62.10) forces dealer call-delta covering toward $96.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-2.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DBD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DBD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (DBD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for DBD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DBD)

✓Walkthrough of DBD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DBD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.81%📐 HORIZONTAL RANGE

2026-11-02O $58.07H $59.14L $58.07C $59.14VOL 685.8K

RES: $105.6SUP: $53.15SMA50: $64.94SMA200: $74.91

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DBD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DBD Butterfly Map → + Track DBD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

14.6%/yr Implied 5Y Growth

vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DBD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DBD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DBD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DBD)

Industrials Rank #226 of 485 ⚔️ PBI vs DBD Full Matrix →

1. Head-to-Head Industrials Peer Comparison (DBD vs. PBI, NATL, VYX, PAR)

Industry: Office Equipment/Supplies/Services (13 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, Diebold Nixdorf Incorporated (DBD) ranks #226 by composite RQD confidence (52/100, grade D+) and #211 by equity capitalization ($1.99B). Within this direct 5-issuer industry benchmark cohort, PBI leads on earnings valuation at 15.6x trailing P/E, while NATL leads on capital efficiency and profitability with 14.4% ROIC and — gross margin. PBI currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with DBD at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DBD ACTIVE Diebold Nixdorf Incorporated	D+	52/100	21.0x	25.3%	11.5%	+1.84%	$1.99B	Benchmark Subject
PBI Pitney Bowes Inc.	C	64/100	15.6x	—	—	-5.62%	$2.26B	/pbi-vs-dbd →
NATL NCR Atleos Corporation	D+	55/100	20.9x	—	14.4%	+0.93%	$3.38B	/natl-vs-dbd →
VYX NCR Voyix Corporation	E	31/100	18.3x	—	1.1%	+3.27%	$1.13B	/vyx-vs-dbd →
PAR PAR Technology Corporation	E	31/100	—	43.5%	-4.9%	+3.55%	$736.3M	/par-vs-dbd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000028823

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Diebold Nixdorf Incorporated (DBD) reported GAAP revenue of $3.81B (+1.5% vs. FY2024 revenue of $3.75B ) , GAAP net income of $94.6M, operating cash flow of $300.7M, and free cash flow of $300.7M (+101.5% YoY). On the balance sheet, DBD closed FY2025 with $3.85B in total assets against $938.5M in total debt (Altman Z-Score: 1.79, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.81B	$94.6M	$300.7M	$300.7M	$3.85B	$938.5M
FY2024 (FY)	2024-12-31	$3.75B	-$16.5M	$149.2M	$149.2M	$3.54B	$927.3M

3. DBD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DBD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DBD compare to PBI and NATL in the Industrials sector?

What are the biggest fundamental strengths and SEC risk factors for DBD?

Where is DBD trading relative to its 50-day, 200-day, and 52-week technical levels?

DBD last traded at $59.14 (+1.84% on volume of 685,821 shares), positioning the stock -8.93% below its 50-day simple moving average ($64.94) and -21.05% below its 200-day simple moving average ($74.91). Across its 52-week range of $52.87 to $92.08, DBD sits at the 16.0% percentile with a 14-day RSI of 39.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($54.35 to $63.93).

DBD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DBD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for DBD.

Direct Sub-Reports: DBD RQD Cockpit DBD 12M Forecast DBD Earnings & Move DBD Dividends & DRIP DBD Insiders & 13F DBD Whale Options DBD Profit Sankey DBD News & Why